Primer: EpimAb Biotherapeutics (EPIM HK) - Apr 2026
Proprietary Technology Platform: EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company that has developed proprietary platforms,...
116 Views
Pre-IPO EpimAb Biotherapeutics - The TCE Pipeline Has Great Potential
TCE assets are in high demand. EpimAb’s TCE pipeline has shown promising data, indicating more licensing cooperation.Short-term valuation could...
348 Views
ECM Weekly (25 August 2025)- Hansoh, Daiichi, IFAST, Guzman, Vikram, Shuandeng, Jiaxin, Forest, Aux
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
584 Views
EpimAb (岸迈生物) Pre-IPO: Differentiated Bispecific Products
China's EpimAb seeks to raise $100 million through Hong Kong listing with CITIC Securities and CMBI as joint sponsors, offering differentiated...
391 Views